NasdaqGM - Delayed Quote USD

ClearBridge All Cap Growth ESG ETF (CACG)

48.59 -1.03 (-2.07%)
At close: 4:00 PM EDT
Loading Chart for CACG
DELL
  • Previous Close 49.62
  • Open 49.38
  • Bid 35.59 x 100
  • Ask 62.83 x 200
  • Day's Range 48.59 - 49.38
  • 52 Week Range 36.56 - 52.68
  • Volume 4,198
  • Avg. Volume 4,693
  • Net Assets 124.87M
  • NAV 49.62
  • PE Ratio (TTM) 38.45
  • Yield 0.30%
  • YTD Daily Total Return 5.30%
  • Beta (5Y Monthly) 1.07
  • Expense Ratio (net) 0.54%

The fund seeks to invest in a diversified portfolio of large, medium and small capitalization stocks that have the potential for above-average long-term earnings and/or cash flow growth and meet its financial and environmental, social and governance (“ESG”) criteria. The fund's subadviser uses a bottom-up investment process that seeks to find inefficiently priced companies with strong fundamentals, incentive-driven management teams, dominant positions in niche markets and/or goods and services that are in high customer demand.

Franklin Templeton Investments

Fund Family

Large Growth

Fund Category

124.87M

Net Assets

2017-05-03

Inception Date

Performance Overview: CACG

Trailing returns as of 4/18/2024. Category is Large Growth.

YTD Return

CACG
5.30%
Category
11.92%
 

1-Year Return

CACG
32.03%
Category
36.45%
 

3-Year Return

CACG
4.49%
Category
7.95%
 

People Also Watch

Holdings: CACG

Top 10 Holdings (42.45% of Total Assets)

SymbolCompany% Assets
AMZN
AMZN 7.09%
NVDA
NVDA 5.66%
MSFT
MSFT 5.36%
META
META 4.73%
AVGO
AVGO 4.04%
UNH
UNH 3.75%
NFLX
NFLX 3.08%
VRTX
VRTX 3.06%
V
V 2.93%
CRWD
CRWD 2.76%

Sector Weightings

SectorCACG
Technology   41.17%
Healthcare   17.59%
Industrials   7.30%
Real Estate   1.12%
Utilities   0.00%
Energy   0.00%

Recent News: CACG

Research Reports: CACG

  • ANIK: Lowering target price to $21.00

    ANIKA THERAPEUTICS INC has an Investment Rating of SELL; a target price of $21.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Medium.

    Rating
    Bearish
    Price Target
     
  • ANIK: Lowering target price to $22.00

    ANIKA THERAPEUTICS INC has an Investment Rating of SELL; a target price of $22.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.

    Rating
    Bearish
    Price Target
     
  • ANIK: Lowering target price to $25.00

    ANIKA THERAPEUTICS INC has an Investment Rating of SELL; a target price of $25.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.

    Rating
    Bearish
    Price Target
     
  • What does Argus have to say about HSKA?

    HESKA CORP has an Investment Rating of HOLD; a target price of $126.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Low.

    Rating
    Neutral
    Price Target
     

Related Tickers